Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

883
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
883

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Leukemia & lymphoma·2026
Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026
Same author

Detection and classification of lymphoma from cell-free methylome data.

NPJ precision oncology·2026
Same author

Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario.

Blood neoplasia·2026
Same author

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Hematological oncology·2026
Same author

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.

Practical radiation oncology·2026

Related Experiment Video

Updated: Mar 11, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

799

Management of Relapsed Diffuse Large B-cell Lymphoma.

Michael Crump1

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Room 5-209, Toronto M5G 2M9, Canada.

Hematology/Oncology Clinics of North America
|November 28, 2016
PubMed
Summary

Second-line treatments for diffuse large B-cell lymphoma (DLBCL) are evolving. Younger patients with chemo-sensitive disease benefit from autologous stem cell transplant (ASCT), while others may consider clinical trials for novel therapies.

Keywords:
Autologous transplantCD20 antibodyPrognosisRelapsed/refractory DLBCLSalvage chemotherapy

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

799
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Diffuse large B-cell lymphoma (DLBCL) treatment options for relapsed or refractory disease are continuously advancing.
  • Current primary therapies often involve rituximab, but resistance necessitates exploring alternative strategies.

Purpose of the Study:

  • To outline current and evolving second-line therapy options for diffuse large B-cell lymphoma (DLBCL).
  • To differentiate treatment approaches based on patient age and disease sensitivity.

Main Methods:

  • Review of current clinical practice guidelines and emerging therapeutic strategies for DLBCL.
  • Analysis of treatment outcomes for different patient subgroups, including younger patients and those refractory to multiple lines of therapy.

Main Results:

  • For younger patients with chemotherapy-sensitive disease, salvage therapy followed by autologous stem cell transplant (ASCT) remains the standard of care.
  • Combination therapies are considered for patients not eligible for ASCT.
  • Patients refractory to two lines of therapy face a poor prognosis, highlighting the need for novel treatment approaches.

Conclusions:

  • Treatment decisions for relapsed/refractory DLBCL should be individualized based on patient factors and disease characteristics.
  • Clinical trial participation is strongly recommended for patients with advanced refractory disease to access novel therapeutic agents.